Cellebrite DI Ltd. (NASDAQ:CLBT) Shares Sold by Greenhaven Road Investment Management L.P.

Greenhaven Road Investment Management L.P. decreased its position in Cellebrite DI Ltd. (NASDAQ:CLBT - Free Report) by 20.4% in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 1,572,093 shares of the company's stock after selling 403,448 shares during the period. Cellebrite DI makes up 12.4% of Greenhaven Road Investment Management L.P.'s portfolio, making the stock its 2nd largest position. Greenhaven Road Investment Management L.P. owned approximately 0.66% of Cellebrite DI worth $30,546,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently made changes to their positions in CLBT. Victory Capital Management Inc. bought a new position in Cellebrite DI in the 4th quarter valued at about $234,000. Raymond James Financial Inc. acquired a new position in shares of Cellebrite DI during the fourth quarter worth $9,995,000. HighTower Advisors LLC acquired a new position in shares of Cellebrite DI during the fourth quarter worth $274,000. Swiss National Bank lifted its holdings in Cellebrite DI by 24.5% in the fourth quarter. Swiss National Bank now owns 150,600 shares of the company's stock valued at $3,318,000 after buying an additional 29,600 shares during the period. Finally, Teacher Retirement System of Texas acquired a new position in Cellebrite DI in the fourth quarter valued at $442,000. Institutional investors and hedge funds own 45.88% of the company's stock.

Analyst Ratings Changes

CLBT has been the subject of several research analyst reports. JPMorgan Chase & Co. decreased their price target on shares of Cellebrite DI from $29.00 to $25.00 and set an "overweight" rating for the company in a research note on Monday, May 12th. Needham & Company LLC restated a "buy" rating and set a $24.00 price target on shares of Cellebrite DI in a research note on Friday, June 6th. Seven research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock presently has an average rating of "Buy" and a consensus price target of $22.43.

Cellebrite DI Stock Performance

Shares of CLBT traded up $0.05 during mid-day trading on Wednesday, hitting $14.31. 897,565 shares of the company traded hands, compared to its average volume of 1,463,500. The stock has a 50-day moving average price of $16.21 and a two-hundred day moving average price of $18.94. Cellebrite DI Ltd. has a 1 year low of $11.90 and a 1 year high of $26.30. The stock has a market cap of $3.43 billion, a price-to-earnings ratio of -14.92, a P/E/G ratio of 2.87 and a beta of 1.28.

Cellebrite DI (NASDAQ:CLBT - Get Free Report) last released its quarterly earnings data on Wednesday, May 14th. The company reported $0.10 EPS for the quarter, beating the consensus estimate of $0.09 by $0.01. The business had revenue of $107.55 million during the quarter, compared to analyst estimates of $109.36 million. Cellebrite DI had a negative net margin of 46.34% and a positive return on equity of 35.36%. Cellebrite DI's quarterly revenue was up 20.0% compared to the same quarter last year. During the same quarter last year, the business earned $0.08 earnings per share. On average, analysts forecast that Cellebrite DI Ltd. will post 0.3 EPS for the current year.

Cellebrite DI Company Profile

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.